Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
22-Dec-2025 | 855.9 | 861.95 | 850 | 853.75 | 5,998 | 3,84,47,002 | 18,234 |
23-Dec-2025 | 852 | 859.4 | 851.8 | 857.4 | 7,935 | 2,70,60,538.55 | 14,947 |
24-Dec-2025 | 857 | 863.85 | 855.05 | 857.2 | 5,422 | 3,52,51,047.2 | 11,994 |
26-Dec-2025 | 863.2 | 863.2 | 851 | 852.2 | 2,589 | 1,47,86,314 | 7,800 |
29-Dec-2025 | 851.9 | 854.95 | 836.55 | 840.45 | 2,669 | 2,19,27,795.95 | 11,294 |
30-Dec-2025 | 838.05 | 841.9 | 834.95 | 836.65 | 4,298 | 2,01,17,952.6 | 14,656 |
31-Dec-2025 | 836.5 | 851 | 835.1 | 846.15 | 3,855 | 3,16,62,877.2 | 18,041 |
01-Jan-2026 | 843 | 849 | 835 | 837.65 | 3,696 | 2,21,02,967.15 | 13,747 |
02-Jan-2026 | 835 | 847.5 | 832.7 | 835.05 | 3,224 | 6,07,58,284.3 | 47,483 |
05-Jan-2026 | 841.75 | 847.95 | 832 | 837.5 | 7,770 | 5,14,32,024.15 | 30,644 |
06-Jan-2026 | 838 | 839.9 | 821.95 | 825.7 | 8,434 | 5,72,85,790.55 | 30,796 |
07-Jan-2026 | 825.7 | 841.9 | 820.85 | 823.7 | 10,005 | 6,11,10,248.3 | 33,565 |
08-Jan-2026 | 825 | 826.85 | 810.6 | 814.75 | 13,101 | 9,97,56,259 | 55,941 |
09-Jan-2026 | 815.8 | 815.8 | 798.1 | 799.95 | 9,684 | 7,16,99,338 | 46,288 |
12-Jan-2026 | 800 | 804.15 | 786 | 796.9 | 9,172 | 4,62,50,222.05 | 27,212 |
13-Jan-2026 | 804.7 | 804.7 | 792.55 | 801.1 | 8,456 | 2,95,23,205.2 | 20,315 |
14-Jan-2026 | 795 | 801.95 | 786.35 | 789.9 | 6,374 | 3,48,23,297.35 | 25,309 |
16-Jan-2026 | 793 | 793.05 | 772.65 | 774.9 | 11,605 | 6,40,19,446.05 | 42,796 |
19-Jan-2026 | 771 | 774.4 | 763.4 | 769.8 | 9,143 | 3,26,05,446.35 | 19,311 |
20-Jan-2026 | 769.9 | 773.9 | 759.05 | 765.15 | 9,134 | 5,30,46,464.25 | 40,201 |
21-Jan-2026 | 762.45 | 764.5 | 747 | 761.8 | 6,894 | 5,29,68,790.3 | 31,867 |
The pharma business also announced that it has already secured final USFDA approvals for Bosutinib Tablets in the 100 mg and 500 mg strengths.
Alembic’s version has been cleared as therapeutically equivalent to Cardizem Tablets, the reference drug marketed by Bausch Health US LLC.
The report closes the regulator’s inspection held between May 26 and May 31, 2025, confirming that the manufacturing units met compliance standards.
According to market research firm IQVIA, the US market for this formulation is estimated at around $94 million for the 12 months ending June 2025.
Alembic’s version is a generic substitute for Tegretol-XR, a medicine originally developed by Novartis.
The total value of the deal stands at around $12 million. The company expects to close the transaction within the next month.
Alembic Pharmaceuticals shares have gained 10% in the last year, dipped 2.8% in the year-to-date, and gained 2.3% in the previous month.
EBITDA was up 9% at ₹286 crore, with EBITDA margin at 16% of total sales, reflecting operating efficiency.
The approved product is the generic equivalent of Tegretol Tablets 200 mg, which was initially developed by Novartis Pharmaceuticals Corporation.
This approval bolsters Alembic's portfolio in the United States market and reinforces its presence in injectable segment
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
